NCT05532254

Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

A Randomized, Single Oral Dose, Two-way Crossover, Open-label, Laboratory Blind, Bioequivalence Study Comparing Aripiprazole From Two Different Drug Products After Oral Administration to Healthy Adult Subjects Under Fasting Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Future University in Egypt · Academic / Other
• Sex: Male
• Age: 35 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate and compare the relative plasma bioavailability and therefore the bioequivalence of two different immediate release products each containing Aripiprazole 10 mg, after administering a single oral dose, to healthy adult subjects under fasting conditions.

Detailed description

Enrolled subjects were randomized in a two-phase, two-sequence, cross-over design to receive a single dose of the test product (T) or the reference product (R) at each phase, under fasting conditions, with a wash-out period of 21 days. Aripiprazole plasma concentration was determined using a validated LC-MS-MS method, followed by Pharmacokinetics, and statistical analysis using Phoenix WinNonlin® software to determine the average bioequivalence.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Aripiprazole 10 mg tablet	an immediate-release tablet containing 10 mg Aripiprazole
DRUG	Abilify® 10 mg tablet	an immediate-release tablet containing 10 mg Aripiprazole

Timeline

• Start date: 2021-02-14
• Primary completion: 2021-03-11
• Completion: 2021-03-11
• First posted: 2022-09-08
• Last updated: 2022-09-08

Locations

1 site across 1 country: Egypt